Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Columbia University
AIDS Malignancy Consortium
AIDS Malignancy Consortium
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Emory University
Weill Medical College of Cornell University
University of California, San Francisco
Bispebjerg Hospital
Scripps Translational Science Institute
UNC Lineberger Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
AIDS Malignancy Consortium
Duke University
City of Hope Medical Center
University of California, San Francisco
AIDS Malignancy Consortium
AIDS Malignancy Consortium
Navidea Biopharmaceuticals
Fred Hutchinson Cancer Center
Desmond Tutu HIV Foundation
Universitas Padjadjaran
UNC Lineberger Comprehensive Cancer Center
ANRS, Emerging Infectious Diseases
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Duke University
University Hospital Virgen de las Nieves
Fred Hutchinson Cancer Center
Instituto Nacional de Saúde, Mozambique
AIDS Malignancy Consortium
Indiana University
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Affiliated Hospital of Guangdong Medical University
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Medstar Health Research Institute
Universitätsklinikum Hamburg-Eppendorf
International Agency for Research on Cancer
AIDS Malignancy Consortium
ANRS, Emerging Infectious Diseases
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)